With the rapid acceleration of T cell engager innovation and the broadening of immunotherapy applications, much of today’s clinical progress remains centered around familiar CD3 based formats and a small number of validated tumor associated antigens. In solid tumors especially, early generation TCE programs continue to cluster around targets such as DLL3, HER2, CLDN6, and PSMA, while autoimmune development is still dominated by mechanisms that deplete pathogenic B or T cell subsets.

As questions grow around how many similar TCEs directed at crowded targets or relying on well-trodden CD3 geometries can meaningfully differentiate in the clinic, the field is increasingly calling for a new wave of innovation that meaningfully addresses durability, toxicity, tumor penetration, co-stimulation, and disease-specific biology.

As the industry’s longest-standing and definitive forum dedicated to immune cell redirecting therapeutics, the 8^th T-Cell Engager Therapeutics Summit is committed to spotlighting the next frontier of TCE science, showcasing the breakthrough engineering strategies, translational insights, and mechanistic advances that will shape the next generation of safer, more potent, and more precisely targeted T cell engagers.